


Asymmetric Total Syntheses of Megacerotonic Acid and Shimobashiric Acid A

Scott W. Krabbe and Jeffrey S. Johnson*

Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States


S Supporting Information

ABSTRACT: The asymmetric total syntheses of the α -benzylidene- γ -butyrolactone natural products megacerotonic acid and shimobashiric acid A have been accomplished in nine and 11 steps, respectively, from simple, commercially available starting materials. The key step for each synthesis is the (arene)RuCl(monosulfonamide)-catalyzed dynamic kinetic resolution-asymmetric transfer hydrogenation (DKR-ATH) of racemic α,δ -diketo- β -aryl esters to establish the absolute stereochemistry. Intramolecular diastereoselective Dieckmann cyclization forms the lactone core, and ketone reduction/alcohol elimination installs the α -arylidene.



Natural products containing an α -benzylidene- γ -butyrolactone¹ elicit a wide variety of biological responses, including antiviral,² anticancer,³ antifungal,⁴ and anti-inflammatory activities.⁵ To date, megacerotonic acid⁶ **1a** and shimobashiric acid A⁷ **1b** are the only known members of this natural product class that contain both C3-aryl and C4-carboxylic acid substituents (Scheme 1).⁸ A racemic total

Scheme 1. Retrosynthetic Analysis



synthesis of megacerotonic acid has been reported,⁹ but its biological activity has not been investigated. The purpose of this communication is to report the first asymmetric total syntheses of megacerotonic acid and shimobashiric acid A via a route that should be amenable to the preparation of unnatural congeners.

Megacerotonic acid was isolated by Takeda and co-workers from *Megaceros flagellaris* in 1990, and no investigation of its biological activity data has been reported to date.⁶ At the time of its isolation, megacerotonic acid was the only known γ -butyrolactone natural product to contain the C2-arylidene-C3-aryl-C4-carboxylic acid substitution pattern. Papin and co-workers⁹ carried out a racemic synthesis, unambiguously establishing its structure. The only other natural γ -butyrolactone known with this substituent array, shimobashiric acid A, was isolated by Murata and co-workers in 2012 from *Keiskea japonica* after its extracts showed hyaluronidase inhibitory

activity.⁷ Although a number of other natural products isolated from these extracts showed biological activity, the isolation of **1b** in a small quantity (1.2 mg) precluded the investigation of its biological activity.

Our laboratory recently reported facile access to enantio-enriched γ -butyrolactones containing the required C3-aryl and C4-carboxylate functionality,¹⁰ potentially providing rapid entry to structures **1a** and **1b**. Approaching the retrosynthetic analysis of these natural products (Scheme 1), we envisioned Heck coupling of α -methylene lactone **2** with the appropriate haloarene (Ar^2 -X), allowing late-stage installation of a variety of benzylidene substituents and providing a modular approach to this class of natural products. Synthetic access to **2** would be achieved by a known three-step procedure utilizing ruthenium catalyzed dynamic kinetic resolution asymmetric transfer hydrogenation (DKR-ATH) of racemic β -aryl- α -keto esters followed by *in situ* diastereoselective lactonization.¹⁰ Racemic β -aryl- α -keto esters **3** can be prepared in a single step using a previously reported glyoxylate Stetter addition.


Initial investigation into this proposed synthetic pathway focused on the optimization of a route to **1a** as we believed the same pathway would also be applicable to **1b** (Scheme 2). DKR-ATH of β -aryl- α -keto ester **3** with concomitant lactonization smoothly provided γ -butyrolactone **4** in high diastereo- and enantioselectivity following a single recrystallization. Bromomethylation using dibromomethane followed by LiCl-promoted Krapcho dealkoxycarbonylation/elimination¹¹ provided α -methylene lactone **2** for investigation of the projected Heck coupling.

Extant methodologies for Heck couplings that deliver exocyclic alkenes are generally limited to β -unsubstituted- or β -alkyl- α -methylidene lactones.¹² Kim and co-workers reported


Received: January 15, 2015

Published: February 20, 2015

Scheme 2. Preliminary Route




the only example of Heck coupling using β -aryl- α -methylidene lactones, and formation of the butenolide was heavily favored over the desired exocyclic alkene.¹³ In our investigations, optimization of this coupling protocol provided arylidene **6a** in only 19% yield (Scheme 3).¹⁴ Additionally, methylidene **2** was unreactive toward cross-metathesis with styrenes.¹⁵

Scheme 3. Access to **6a** via Heck Coupling

Consequently, we turned our attention to an alternative route from lactone **4**, which would allow late stage installation of different benzylidene substituents (Scheme 4). Krapcho dealkoxycarbonylation of lactone **4** provided lactone **7** in good yield.¹⁶ Aldol reaction of lactone **7** with *p*-anisaldehyde followed by acid catalyzed elimination provided **6a**.¹⁷


Scheme 4. Krapcho Dealkoxycarbonylation/Aldol/Elimination Sequence



This modified route provided key intermediate **6a** in a disappointing three step overall yield of 20%; however, the viability of alcohol elimination prompted us to consider a new retrosynthetic analysis for alcohol **8a** (Scheme 5). In this proposed sequence, access to **8a** would be provided by reduction of β -keto lactone **9**, which would arise from (4 + 1)-annulation between a synthetic equivalent of **10** and a phosgene surrogate (**11**). DKR-ATH of α,δ -diketo- β -aryl ester **12** would establish the absolute stereochemistry.¹⁰

α,δ -Diketo- β -aryl ester **12a** was prepared via *N*-heterocyclic carbene-catalyzed Stetter reaction of ethyl glyoxylate with enone **13a**¹⁰ and was directly submitted to (arene)RuCl-

Scheme 5. Revised Retrosynthetic Analysis




(monosulfonamide) catalyzed DKR-ATH, providing alcohol **14a** in excellent yield with high diastereo- and enantioselectivity (Scheme 6A).¹⁰ Installation of the requisite activated carbonyl functionality was achieved with 1,1'-carbonyldiimidazole to give tricarbonyl **15a**.¹⁸ Selective enolate formation with potassium bis(trimethylsilyl)amide (KHMDs) led to a diastereoselective Dieckmann cyclization that delivered **9a**. A subsequent ketone reduction to alcohol **8a** was achieved with Pd/C and H₂.¹⁹ Dehydration to enone **6a** (Scheme 6B) was promoted by polymer supported perfluorosulfonic acid (Nafion SAC-13). In our hands, the reported ester epimerization and hydrolysis⁹ of **6a** using lithium methoxide/methanol resulted in a number of undesired byproducts. Switching to sodium *tert*-butoxide in *tert*-amyl alcohol smoothly provided acid **16a** as a 14:1 mixture of chromatographically inseparable diastereomers. Boron tribromide-mediated demethylation and purification by reverse phase HPLC completed the first asymmetric total synthesis of megacerotic acid **1a** in nine steps and 11% overall yield from commercially available materials.

The route to **1b** was identical to **1a** through the synthesis of alcohol **8b** (Scheme 6A). When **8b** was submitted to the elimination conditions optimized for **8a** (Scheme 6B), enone **6b** was not formed, and only partial Boc deprotection was observed, even at elevated temperatures (100 °C). We sought a solution to this problem that would obviate the necessity of electron rich arenes and found that the Burgess reagent met this need, providing enone **6b** as well as less electron rich α -benzylidene- γ -butyrolactones **6c** and **6d**, prepared via the same synthetic route (Scheme 7).²⁰


tert-Butoxycarbonyl removal, epimerization at C4, and hydrolysis provided **16b** in good overall yield as a 14:1 mixture of chromatographically inseparable diastereomers. Acetal deprotection and purification by reverse phase HPLC provided shimobashiric acid **1b** in 11 steps and 5% overall yield from commercially available material.²¹

In conclusion, we have reported the first asymmetric total syntheses of structurally unique α -benzylidene- γ -butyrolactones megacerotic acid and shimobashiric acid A via a route amenable to the synthesis of analogues. This route utilized DKR-ATH to establish the absolute stereochemistry in excellent enantio- and diastereoselectivity, and diastereoselective Dieckmann cyclization formed the lactone core in high overall yield. Selective ketone reduction and subsequent elimination formed the α -benzylidene with excellent *E:Z* selectivity. Epimerization at C4, hydrolysis, and phenol deprotection concluded the first asymmetric total syntheses of megacerotic acid and shimobashiric acid A. Screening of the synthesized natural products and analogues thereof for relevant biological activity is currently underway and will be reported in due course.

Scheme 6. Synthetic Route to Megaceronic Acid and Shimobashiric Acid A



Scheme 7. Eliminations with the Burgess Reagent



■ ASSOCIATED CONTENT

S Supporting Information

Experimental procedures, characterization, and spectral data for all compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: jsj@unc.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The project described was supported by Award No. R01 GM084927 from the National Institute of General Medical Sciences. S.W.K. acknowledges a National Science Foundation Graduate Research Fellowship. The authors thank Professor Marcey Waters, Brendan Peacor, and Nicholas Pinkin (UNC) for use of and assistance with reverse phase HPLC systems, and Professor Michael Crimmins (UNC) for helpful discussions. A natural sample of shimobashiric acid A was generously provided by Professor Toshihiro Murata (Tohoku Pharmaceutical University).

■ REFERENCES

- (1) Kitson, R. R. A.; Millemaggi, A.; Taylor, R. J. K. *Angew. Chem., Int. Ed.* **2009**, *48*, 9426.
- (2) (a) Tuchinda, P.; Kornsakulkarn, J.; Pohmakotr, M.; Kongsaree, P.; Prabpai, S.; Yoosook, C.; Kasit, J.; Napsawad, C.; Sophasan, S.; Reutrakul, V. *J. Nat. Prod.* **2008**, *71*, 655. (b) Wen, C.-C.; Kuo, Y.-H.; Jan, J.-T.; Liang, P.-H.; Wang, S.-Y.; Liu, H.-G.; Lee, C.-K.; Chang, S.-T.; Kuo, C.-J.; Lee, S.-S.; Hou, C.-C.; Hsiao, P.-W.; Chien, S.-C.; Shyur, L.-F.; Yang, N.-S. *J. Med. Chem.* **2007**, *50*, 4087. (c) Baroudy, B.; Archambault, J. WO 2006/088824 A2, August 24, 2006.
- (3) (a) Mansoor, T. A.; Borralho, P. M.; Luo, X.; Mulhovod, S.; Rodrigues, C. M. P.; Ferreira, M.-J. U. *Phytomedicine* **2013**, *20*, 923. (b) Ho, P.-J.; Chou, C.-K.; Kuo, Y.-H.; Tu, L.-C.; Yeh, S.-F. *Life Sci.* **2007**, *80*, 493. (c) Dall'Acqua, S.; Viola, G.; Piacente, S.; Cappelletti, E. M.; Innocenti, G. *J. Nat. Prod.* **2004**, *67*, 1588. (d) Chang, S.-T.; Wang, D. S.-Y.; Wua, C.-L.; Shiah, S.-G.; Kuo, Y.-H.; Chang, C.-J. *Phytochemistry* **2000**, *55*, 227. (e) Natural product derivatives: Ding,

Y.-H.; Fan, H.-X.; Long, J.; Zhang, Q.; Chen, Y. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 6087.

(4) Hwang, E.-I.; Yun, B.-S.; Kim, Y.-K.; Kwon, B.-M.; Kim, H.-G.; Lee, H.-B.; Jeong, W.-J.; Kim, S.-U. *J. Antibiot.* **2000**, *53*, 903.

(5) Cho, J. Y.; Park, J.; Kim, P. S.; Yoo, E. S.; Baik, K. U.; Park, M. H. *Biol. Pharm. Bull.* **2001**, *24*, 167.

(6) Takeda, R.; Hasegawa, J.; Shinozaki, M. *Tetrahedron Lett.* **1990**, *31*, 4159. Takeda, R.; Hasegawa, J.; Shinozaki, M. *Proc. Phytochem. Soc. Eur.* **1990**, *29*, 201.

(7) Murata, T.; Miyase, T.; Yoshizaki, F. *Chem. Pharm. Bull.* **2012**, *60*, 121.

(8) For α -benzylidene- γ -butyrolactone natural products with C3-aryl-C4-ester substitution (two cases) see ref 1. For α -benzylidene- γ -butyrolactone natural products with C3-aryl-C4-methanol substitution (two cases) see: Chung, Y.-M.; Wang, H.-C.; El-Shazly, M.; Leu, Y.-L.; Cheng, M.-C.; Lee, C.-L.; Fang-Rong Chang, F.-R.; Wu, Y.-C. *J. Agric. Food Chem.* **2011**, *59*, 9219.

(9) (a) Brown, E.; Dhal, R.; Papin, N. *Tetrahedron* **1995**, *51*, 13061.

(b) Papin, N.; Dhal, R.; Brown, E. *Nat. Prod. Lett.* **1994**, *4*, 303.

(10) (a) Steward, K. M.; Corbett, M. T.; Goodman, C. G.; Johnson, J. S. *J. Am. Chem. Soc.* **2012**, *134*, 20197. (b) Steward, K. M.; Gentry, E. C.; Johnson, J. S. *J. Am. Chem. Soc.* **2012**, *134*, 7329.

(11) Bukowska, M.; Kolodziejek, W.; Prejzner, J. *Polym. J. Chem.* **1990**, *64*, 573.

(12) (a) Belovodskii, A. V.; Shults, E. E.; Shakirov, M. M.; Bagryanskaya, I. Y.; Gatilov, Y. V.; Tolstikov, G. A. *Russ. J. Org. Chem.* **2010**, *46*, 1719. (b) Han, C.; Barrios, F. J.; V. Riofski, M. V.; David, A.; Colby, D. A. *J. Org. Chem.* **2009**, *74*, 7176. (c) Arcadi, A.; Chiarini, M.; Marinelli, F.; Berente, Z.; Koll r, L. *Eur. J. Org. Chem.* **2001**, 3165. (d) Arcadi, A.; Chiarini, M.; Marinelli, F.; Berente, Z.; Koll r, L. *Org. Lett.* **2000**, *2*, 69.

(13) Kim, S. H.; Kim, K. H.; Lee, H. J.; Kim, J. N. *Tetrahedron Lett.* **2013**, *54*, 329.

(14) Under the conditions reported, butenolide formation was not observed and the mass balance resides in a product incorporating two units of **2**.

(15) (a) Raju, R.; Allen, L. J.; Le, T.; Taylor, C. D.; Howell, A. R. *Org. Lett.* **2007**, *9*, 1699. (b) Moilse, J.; Arseniyadis, S.; Cossy, J. *Org. Lett.* **2007**, *9*, 1695.

(16) Krapcho, A. P. *Synthesis* **1982**, 893.

(17) Mulzer, J.; Chucholowski, A. *Angew. Chem.* **1986**, *98*, 632.

(18) Armstrong, A.; Li, W. *N,N'*-Carbonyldiimidazole. *e-EROS Encyclopedia of Reagents for Organic Synthesis* **2007**, DOI: 10.1002/9780470842898.rc024.pub2.

(19) Pohmakotr, M.; Sampaongoen, L.; Issaree, A.; Tuchinda, P.; Reutrakul, V. *Tetrahedron Lett.* **2003**, *44*, 6717.

(20) (a) Khapli, S.; Dey, S.; Mal, D. *J. Indian Inst. Sci.* **2001**, *81*, 461.

(b) Burgess, E. M.; Penton, H. R., Jr.; Taylor, E. A. *J. Org. Chem.* **1973**, *38*, 26. (c) Atkins, G. M.; Burgess, E. M. *J. Am. Chem. Soc.* **1968**, *90*, 4744.

(21) The lower overall yield obtained for shimobashiric acid **A** in comparison to megacerotonic acid is a consequence of the Claisen–Schmidt condensation used in the synthesis of **13b** (46% yield).